1.. Introduction
================

Tremendous effort has been devoted to discovering biomarkers that can be used in prediction of disease occurrence and progression. Clinical covariates---such as age, gender, blood pressure, tumor size and grade, and smoking and drinking history---have been extensively used and shown to have satisfactory predictive power ([@b6-cin-03-371]; [@b11-cin-03-371]). Clinical risk factors have sound biological implications and are usually easy to measure and of low dimensionality.

Recent developments in high throughput techniques, such as microarray, make it possible to measure human genomic features on a global scale. Biomedical studies with high dimensional gene expressions measured along with disease outcomes are becoming commonplace ([@b3-cin-03-371]; [@b14-cin-03-371]; [@b1-cin-03-371]). Scientists have shown that using genomic biomarkers selected from microarray measurements may provide satisfactory prediction of disease status. See for example [@b17-cin-03-371] and [@b15-cin-03-371], among others. Using genomic measurements provides an alternative, satisfactory way of disease prediction beyond clinical covariates.

Clinical and genomic covariates may correspond to different aspects of causation of diseases. Consider the occurrence of lung cancer as an example. Studies have shown that smoking, which is a clinical covariate, is the best predictor of lung cancer occurrence. How ever, genetic defection has also been shown to contribute to occurrence of lung cancer. By combining smoking history with genomic measurements, prediction with better sensitivity and specificity (than using smoking or genetic defection alone) can be achieved. Such an improvement has been observed with other diseases ([@b13-cin-03-371]; [@b12-cin-03-371]). It is thus of great interest to develop statistical methodologies that can effectively combine low dimensional clinical and high dimensional genomic measurements in disease prediction.

In [@b4-cin-03-371], a small number of genes are first selected and then combined with clinical covariates in predictive model building. Such an approach, although very easy to implement, ignores clinical covariates in gene selection and may lead to sub optimal results. In [@b7-cin-03-371], adjusting for clinical covariates in detecting differential genes is investigated in the linear regression and FDR framework. In that study, the goal is to detect differentially expressed genes, and predictive model building is not considered. A sufficient dimension reduction approach is proposed by [@b8-cin-03-371] in the framework of survival analysis, where two lymphoma survival datasets are analyzed. The sufficient dimension reduction method uses linear combinations of all covariates, which makes it hard to interpret individual covariate effects. In a breast cancer study with a binary response representing the disease status, [@b16-cin-03-371] proposes the iterative 1-RELIEF approach. It is not clear how to extend that approach to studies with other clinical outcomes such as survival.

In this article, we propose a new regularized method, Cov-TGDR (Covariate-Adjusted Threshold Gradient Directed Regularization), for combining different type of covariates in disease prediction. The proposed approach is capable of simultaneous biomarker selection and predictive model building. It has great flexibility by allowing different degrees of regularization for different type of covariates. The rationale is that clinical and genomic covariates are not directly comparable. Different regularization should thus be considered. Similar arguments have been made in [@b8-cin-03-371] and [@b16-cin-03-371]. In our study, we only consider two type of covariates, namely clinical and genomic. In principle, the proposed Cov-TGDR can be used when more than two type of covariates are present.

In Section 2, we first present the data and models that we consider. We use logistic regression for binary classification and Cox model for right censored survival analysis as examples. The proposed Cov-TGDR is described in Section 3. Tuning parameter selection and prediction evaluation are also discussed. We present analysis of the Breast Cancer data (which has a binary outcome) in Section 4 and analysis of the Follicular lymphoma data (which has a right censored survival outcome) in Section 5, respectively. The article concludes with discussions in Section 6.

2.. Data and Model
==================

Let *Y* be the clinical outcome of interest. Let *Z* = (*W*, *X*) be the length *d* vector of covariates. Specifically, let *W* be the length *d*~1~ vector consisting of clinical covariates; and let *X* be the length *d*~2~ vector of gene expressions, where *d*~1~ + *d*~2~ = *d*. In a typical biomedical study, *d*~1~ ∼ 10 while *d*~2~ ∼ 10^3--4^. For simplicity of notations, we assume there are only two different sets of covariates. The proposed approach can be easily extended to multiple sets of covariates.

Suppose that *Y* is associated with *Z* through the model *Y* ∼ *φ*(*β′Z*) with known regression function *φ* and unknown regression coeffcient *β*. We are particularly interested in classification and survival analysis problems where both clinical and genomic covariates are measured along with disease outcomes due to their extensive applications.

2.1. Binary classification
--------------------------

For classification problems, *Y* is the categorical variable denoting the disease status. For simplicity of notations, we focus on binary classification only. Suppose that *Y* = 1 representsthe presence and *Y* = 0 indicates the absence of disease. We assume the commonly used logistic regression model, where the logit of the conditional probability is $$\text{logit}(P(Y = 1|Z) = \alpha + \beta^{\prime}Z$$Here *β* is the length *d* vector of regression coeffcient and α is the intercept. Based on a random sample of *n* iid observations (*Y~i~*, *Z~i~*)*, i* = 1, \..., *n*, the maximum likelihood estimator is defined as (*α̂*, *β̂*) = *argmax~α,\ β~* *R~n~*(*α*, *β*), where $$\begin{array}{l}
{R_{n}(\alpha,\beta) = \sum\limits_{i = 1}^{n}{Y_{i}\text{log}\left( \frac{\text{exp}(\alpha + \beta^{\prime}Z_{i})}{1 + \text{exp}(\alpha + \beta^{\prime}Z_{i})} \right)}} \\
{\quad + (1 - Y_{i})\text{log}\left( \frac{1}{1 + \text{exp}\left( {\alpha + \beta^{\prime}Z_{i}} \right)} \right)} \\
\end{array}$$Since *α* is usually of secondary interest, we simply write *R~n~*(*α*, *β*) as *R~n~*(*β*).

2.2. Cox survival analysis
--------------------------

For right censored survival data, *Y* = (*T*, Δ), where *T* = *min*(*U*, *V*) and Δ = *I* (*U* ≤ *V*). Here *U* and *V* denote the event and censoring times, respectively. The most widely used model for censored survival data is the Cox model ([@b2-cin-03-371]) which assumes that the conditional hazard function $$\lambda(u|Z) = \lambda_{0}(u)\text{exp}(\beta^{\prime}Z)$$where λ~0~ is the unknown baseline hazard function and *β* is the unknown regression coeffcient. Based on a random sample of *n* iid observations (*Y~i~*, *Z~i~*), *i* = 1, \..., *n*, the partial likelihood estimator is defined as the value *β̂* that maximizes $$R_{n}(\beta) = \prod\limits_{i = 1}^{n}\left\{ \frac{\text{exp}(\beta^{\prime}Z_{i})}{\sum_{j \in r_{i}}{\text{exp}{({\beta^{\prime}Z_{i}})}}} \right\}^{\delta_{i}}$$where *r~i~* = {*j: T~j~* ≥ *T~i~*} is the risk set at time *T~i~*.

For both logistic classification and Cox survival analysis, *β* can be estimated by maximizing the continuously differentiable likelihood or partial likelihood functions, which depend on *β* only. The proposed Cov-TGDR is generally applicable if other parametric or semiparametric models are assumed, provided that smooth objective functions are available.

3.. Cov-TGDR
============

3.1. Algorithm
--------------

The proposed Cov-TGDR is a gradient searching approach. We refer to [@b5-cin-03-371] for background and general discussions on such an approach. Let Δ*ν* be a small positive increment. In the implementation of our approach, we choose Δ*ν* = 1 × 10^−3^. Denote *ν~k~* = *k* × Δ*ν* as the index for the point along the parameter path after *k* steps. Let *β* (*ν~k~*) denote the parameter estimate corresponding to *ν~k~*. Denote 0 ≤ τ~1~,τ~2~ ≤ 1 as the threshold values for clinical and genomic covariates, respectively. The proposed Cov-TGDR consists of the following iterative steps: Initialize *β* (0) = 0 and *ν*~0~ = 0.With current estimate *β*, compute the negative gradient *g*(*ν*) = −*∂R~n~*(*β*)*/∂β*. Denote the *jth* component of *g*(*ν*) as *g~j~*(*ν*). If max*j* {\| *g~j~*(*ν*)\|} = 0, stop the iteration.Compute the length-*d* threshold vector *f* (*ν*), where $$\begin{array}{l}
{f_{j}(v) = \, I\left\{ {|{g_{j}(v)}|} \geq \tau_{1} \times \underset{1 \leq l \leq d_{1}}{\text{max}}{|{g_{l}(v)}|} \right\},} \\
{\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\text{for}\, 1 \leq j \leq d_{1}} \\
{f_{j}(v) = \, I\left\{ {|{g_{j}(v)}|} \geq \tau_{2} \times \underset{l > d_{1}}{\text{max}}\,{|{g_{l}(v)}|} \right\},} \\
{\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\,\text{for}\, j > d_{1}} \\
\end{array}$$Update *β* (*ν~k~* + Δ*ν*) = *β* (*ν~k~*) − Δ*ν* × *g*(*ν~k~*) × *f* (*ν~k~*) and update *ν~k~* by *ν~k~* + Δ*ν*, where the product of *f* and *g* is component-wise.Steps 2--4 are repeated *k* times. The number of iterations *k* is determined by cross validation.

The Cov-TGDR uses a thresholding and variable selection scheme quite different from the TGDR in [@b5-cin-03-371]. Particularly in Step 3, thresholding is carried out for different sets of covariates separately. The rationale is that different type of covariates are not directly comparable---one unit increase in gene expressions may have quite different implications from one unit increase in clinical covariates. In addition, genomic covariates usually have a much higher dimensionality than clinical covariates. Variable selection is much more important for genomic covariates than for clinical covariates, which demands a higher degree of regularization for genomic covariates. A fair approach should consider thresholding comparisons within each type of covariates separately, as in Step 3.

Loosely speaking, the Cov-TGDR carries out TGDR for each type of covariates separately. The properties of *β* are determined jointly by *k* and (*τ*~1~,*τ*~2~). When (*τ*~1~,*τ*~2~) = (0, 0), the Cov-TGDR does not carry out biomarker selection and generates estimates similar to the ridge regression. When (*τ*~1~ = 0,*τ*~2~ \> 0), the Cov-TGDR carries out variable selection with gene expressions, while adjusting for clinical covariates without any variable selection. When (*τ*~1~ \> 0,*τ*~2~ \> 0), variable selections are carried out for both clinical and genomic covariates. By allowing *τ*~1~ ≠ *τ*~2~, the proposed Cov-TGDR is more flexible than the TGDR.

In addition, it takes into account clinical covariates when estimating and selecting variables with gene expressions. It is thus more reasonable than the naive approach, where TGDR estimations are carried out separately for clinical and genomic covariates.

3.2. Tuning parameter selection
-------------------------------

We select the tuning parameters *k* and (*τ*~1~,*τ*~2~), which jointly determine the characteristics of the estimator, using the following two-step approach. First, we choose the tuning parameter *k* for any fixed (*τ*~1~,*τ*~2~) using the *V*-fold cross validation ([@b18-cin-03-371]) as follows. Partition the data randomly into *V* non-overlapping subsets of equal sizes. Choose *k* to maximize the cross-validated objective function $$CV(k) = \sum\limits_{\upsilon = 1}^{V}{\lbrack R_{n}(\beta^{( - \upsilon)}) - R_{n}^{( - \upsilon)}(\beta^{( - \upsilon)})\rbrack}$$where *β*^(−^*^υ^*^)^ is the Cov-TGDR estimate of *β* based on data without the *υ*th subset for a fixed *k* and *R~n~*^(−^*^υ^*^)^ is the objective function *R~n~* evaluated without the *υ*th subset. Considering the relatively small sample sizes, we set *V* = 5 in our study.

After cross validation over *k*, model features for different (*τ*~1~,*τ*~2~) can be obtained. We choose parsimonious models with relatively large CV scores. A similar approach has been adopted in [@b10-cin-03-371] and references therein.

3.3. Evaluation
---------------

Prediction evaluation can be based on the following Leave-One-Out (LOO) approach. For *i* = 1, \..., *n*, Remove the *i*th subject.For the reduced dateset with size *n* − 1, carry out the V-fold cross validation and Cov-TGDR estimation. Denote this estimate as *β̂*^(−^*^i^*^)^.Compute the prediction score *β̂*^(−^*^i^*^)^′ *Z~i~* for the removed subject.

A prediction index can then be computed. For binary classification, class probabilities can be computed from the prediction scores and the logistic model. We use probability 0.5 as the cutoff and predict disease status for each subject. The prediction index can be chosen as the prediction error. For censored survival data, we dichotomize the prediction scores at their median and create two hypothetical risk groups. We then compare the survival functions of the two risk groups. The logrank statistic, which has a Chi-squared distribution with degree of freedom one, is taken as the prediction index.

4.. Breast Cancer Study
=======================

Breast cancer is the second leading cause of deaths from cancer among women in the United States. Despite major progresses in breast cancer treatment, the ability to predict the metastatic behavior of tumor remains limited. The Breast Cancer study was first reported in [@b17-cin-03-371]. 97 lymph node-negative breast cancer patients 55 years old or younger participated in this study. Among them, 46 developed distant metastases within 5 years (metastatic outcome coded as 1) and 51 remained metastases free for at least 5 years (metastatic outcome coded as 0).

Clinical covariates collected include age, tumor size, histological grade, angioinvasion, lymphocytic infiltration, estrogen receptor (ER), and progesterone receptor (PR) status. Expression levels for 24481 gene probes were collected. We refer to [@b17-cin-03-371] for more details on experimental setup. The goal of this study is to build a statistical model that can accurately predict the risk of distant recurrence of breast cancer in a five-year post-surgery period. The dataset is publicly available at *<http://www.rii.com/publications/2002/vantveer.html>.*

We first pre-process gene expression data as follows: Remove genes with more than 30% missing measurements.Fill in missing gene expression measurements with median values across samples.Normalize gene expressions to have zero means and unit variances.Compute the simple correlation coefficients of gene expressions with the binary outcome.Select the 500 genes with the largest absolute values of correlation coefficients.

It is reasonable to expect that the number of "interesting" genes is much less than 500 (see [@b10-cin-03-371] and references therein); In addition, including many "noisy" genes in the biomarker selection and model building may lead to less satisfactory results. We thus conduct gene screening prior to the analysis and select only the top 500 genes ([@b16-cin-03-371]; [@b9-cin-03-371]).

The proposed Cov-TGDR is used to analyze the Breast Cancer data. The 5-fold cross validation selects *k* = 884 and (*τ*~1~,*τ*~2~) = (1.0, 0.9) as the optimal tunings. We show the parameter paths as a function of *k* for (*τ*~1~,*τ*~2~) = (1.0, 0.9) in [Figure 1](#f1-cin-03-371){ref-type="fig"}. The vertical lines correspond to *k* = 884. Since both threshold values are large, the parameter paths look like Lasso paths -- they start with all estimates equal to zero; the estimates remain sparse for moderate to large *k* ; and the estimates eventually become dense as *k* → ∞. Similar phenomenon has been observed in [@b5-cin-03-371] and [@b10-cin-03-371].

With the optimal tuning, the final predictive model includes 3 (out of 7) clinical covariates and 51 (out of 500) genomic biomarkers. We list covariates with nonzero estimated coeffcients in [Table 1](#t1-cin-03-371){ref-type="table"}. The three important clinical covariates are age, tumor diameter, and tumor grade, which have long been used as risk factors for predicting breast cancer. Especially, increase of tumor size or grade indicates worsening or proliferation of tumor, which leads to higher likelihood of cancer occurrence. Moreover, our analysis shows that after ad justing for other risk factors, older people are less likely to develop breast cancer. We note that this conclusion cannot be extended to the general population, since the current study only included patients 55 years old or younger. We also provide systematic names and corresponding estimates for identified genes. Gene names and corresponding annotations can be found from the data website and *<http://www.ncbi.nlm.nih.gov/>*. Many of the identified genes have been shown to be associated with breast cancer occurrence in independent studies. We refer to [@b17-cin-03-371] for detailed discussions of gene functions.

For comparison, we also consider three closely related alternatives: (1) Clinical-simple: only clinical covariates are used in the analysis. Since the number of clinical covariates is less than the sample size, logistic model without any regularization can be fitted; (2) Clinical-TGDR: only clinical covariates are used in the analysis, and we use TGDR for regularization. With the TGDR, tuning parameters include the number of iterations *k* and threshold *τ*, (3) Gene-TGDR: only gene expressions are used. TGDR is employed for gene selection and regularized estimation. For alternative approaches (2) and (3), we also use the 5-fold cross validation to select optimal tunings. Prediction evaluation is carried out for all four approaches using the LOO described in Section 3.3. In our estimation, we conduct gene screening prior to the analysis. In the evaluation, for each reduced dataset with size *n* − 1, we also carry out gene screening and select (possibly different sets of) 500 top genes. Since gene screening is included in the LOO, the prediction evaluation has no selection bias.

Estimation and prediction results are summarized in [Table 2](#t2-cin-03-371){ref-type="table"}. We can see that using clinical covariates alone without any regularization results in less satisfactory prediction. With clinical covariates, using TGDR for regularization can reduce model size and increase prediction power. Using gene expressions alone can lead to improved prediction, with the larger model as payoff. Prediction can be further improved by using both clinical and genomic covariates, although the resulted model is larger than all alternatives.

5.. Follicular Lymphoma Study
=============================

Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma, accounting for about 22 percent of all cases. A study was conducted to determine whether the survival risks of patients with follicular lymphoma can be predicted by the gene-expression profiles of the tumors and standard clinical risk factors at diagnosis ([@b3-cin-03-371]). Detailed experiment setup and raw data can be accessed at *<http://llmpp.nih.gov/FL/>*.

Fresh-frozen tumor-biopsy specimens and clinical data from 191 untreated patients who had received a diagnosis of follicular lymphoma between 1974 and 2001 were obtained. The median age at diagnosis was 51 years (range: 23 to 81), and the median follow up time was 6.6 years (range: less than 1.0 to 28.2). The median follow up time among patients alive at last follow up was 8.1 years. Eight records with missing survival information are excluded from the analysis.

Clinical covariates measured include extra nodal site, age, normalized LDH, performance status, stage and IPI.1 (IPI value equal to 2 or 3), and IPI.2 (IPI value equal to 4 or 5). We remove subjects with missing clinical covariate measurements. 156 subjects are included in the Cov-TGDR analysis. Affymetrix U133A and U133B microarray genechips were used to measure gene expression levels. A log2 transformation was first applied to the Affymetrix measurements. We filter the 44928 gene measurements with the following criteria: (1) the max expression value of each gene across 156 samples must be greater than the median max expressions; and (2) the max--min expressions should be greater than their median. 6506 out 44928 genes pass the above unsupervised screening. We further compute the correlation coeffcients of the uncensored survival times with gene expressions. The 500 genes with the largest absolute values of the correlation coeffcients are selected.

We apply the proposed Cov-TGDR. Parameter paths similar to those shown in [Figure 1](#f1-cin-03-371){ref-type="fig"} can be obtained and are omitted here. With the Cov- TGDR, 6 (out of 7) clinical covariates and 23 (out of 500) genomic covariates are selected in the final model. We provide covariates with nonzero estimated coeffcients in [Table 3](#t3-cin-03-371){ref-type="table"}. All measured clinical covariates have importance influences on survival risks. For the IPI measurement, only IPI.1 (IPI value equal to 2 or 3) is important. Increase of any clinical covariates will lead to increased survival risk. For gene expressions, with the Affymetrix feature IDs provided in [Table 3](#t3-cin-03-371){ref-type="table"}, gene names and corresponding biological functions can be found from *<http://llmpp.nih.gov/FL/>*. Many identified genes have been confirmed by independent studies to be associated with survival risks in lymphoma patients. We omit such discussions here.

For the Cov-TGDR and alternative approaches, model estimation and prediction results are summarized in [Table 4](#t4-cin-03-371){ref-type="table"}. As discussed in Section 3.3, we use the logrank statistic as the prediction index for censored survival data, with larger logrank statistic indicating more powerful prediction. We can see from [Table 4](#t4-cin-03-371){ref-type="table"} that using clinical covariates alone can lead to quite satisfactory predictions, with logrank statistics 17.9 and 18.1 and corresponding p-values \<0.001. Using gene expression data alone, 31 genes are selected with the TGDR. The prediction logrank statistic is 4.0, corresponding to p-value 0.045. Prediction can be improved by using both clinical and genomic covariates (logrank statistic 23.9, p-value \< 0.001).

6.. Discussions
===============

Given that clinical and genomic factors may contribute to different aspects of disease occurrence, it is important to use both for predicting disease status. We propose the Cov-TGDR method, which can achieve improved prediction by effectively combining those two type of covariates. The proposed Cov-TGDR is more flexible than the TGDR by allowing different degrees of regularization for different type of covariates. Especially, our numerical studies suggest that Cov-TGDR usually has *τ*~1~ ≤ *τ*~2~, i.e. less regularization is employed for clinical covariates. Another valuable feature of the Cov-TGDR is that the computational cost is small. For the Breast Cancer data, cross validation and estimation combined take less than two minutes. Compared to existing approaches, the Cov-TGDR generates smaller models than the sufficient dimension reduction method of [@b8-cin-03-371]. The Cov- TGDR estimation results are thus easier to interpret. Compared to the 1-RELIEF approach of [@b16-cin-03-371], the proposed Cov-TGDR depends less on the form of the objective function. It can be easily adapted to studies with other type of outcomes and models.

Like in [@b8-cin-03-371] and [@b16-cin-03-371], the proposed Cov-TGDR is built on an existing regularization method (i.e. TGDR). However, they differ significantly in terms of thresholding and variable selection scheme. The two presented studies and other examples (not presented here) show that improved prediction can be achieved with the proposed Cov-TGDR. We note that the improvement may not be as dramatic as one may expect. However, considering the difficulties with predicting status of complicated diseases such as cancer, even very small improvement may have extremely important clinical implications, as has been observed in previous studies ([@b8-cin-03-371]).

One drawback of our study is that no theoretical justification is available for the proposed Cov- TGDR. The proposed estimate is a non-linear function of the observations, which makes it difficult to establish its theoretical properties, such as consistency in terms of variable selection under reasonable conditions. Our limited numerical study establishes the Cov-TGDR's satisfactory empirical performance. More studies are needed to understand its theoretical properties.

The work of Huang was supported in part by NIH grant NCI/NIH P30 CA 086862-06. We wish to thank two anonymous reviewers for their insightful comments.

**Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the Creative Commons Attribution By licence. For further information go to: <http://creativecommons.org/licenses/by/3.0/>**
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###### 

Breast Cancer Data: Cov-TGDR estimation. Variable: variable name (clinical) or systematic name (genomic).

  **Variable**          **Estimate**   **Variable**     **Estimate**
  --------------------- -------------- ---------------- --------------
  Clinical covariates                                   
  age                   −0.193                          
  diameter              0.090                           
  grade                 0.214                           
                                                        
  Genomic covariates                                    
  AB033032              0.007          AJ011306         −0.214
  Contig5816_RC         0.169          NM_013438        0.045
  Contig35148_RC        −0.368         NM_004994        0.142
  Contig46909_RC        −0.230         AL080059         0.660
  Contig23356_RC        0.097          Contig42563_RC   0.087
  Contig35229_RC        −0.134         NM_006544        0.159
  Contig28433_RC        −0.014         NM_005850        0.005
  NM_003366             −0.068         Contig64861_RC   0.194
  NM_020120             0.038          AF055033         0.514
  NM_020123             0.343          NM_016017        0.037
  NM_020132             0.012          Contig47544_RC   0.674
  U72507                −0.089         Contig48697_RC   0.029
  Contig6238_RC         −0.116         NM_016361        −0.174
  AF052087              −0.083         NM_016448        0.029
  NM_005007             −0.082         Contig412_RC     −0.510
  AB018337              0.270          NM_016564        0.445
  AB040969              0.010          NM_018089        0.178
  NM_012341             −0.033         D13540           0.089
  Contig47042           0.189          U79298           −0.177
  Contig38438_RC        −0.096         NM_000127        0.234
  X67055                −0.005         NM_019018        −0.074
  NM_003862             −0.138         NM_000207        −0.049
  NM_003882             −0.083         AL050227         −0.010
  AF131819              0.356          Contig22253_RC   −0.012
  NM_014003             0.120          NM_000801        0.059
  NM_005393             0.304                           

###### 

Analysis of Breast Cancer Data. \# clinical: number of clinical variables. \# gene: number of gene expressions. Tuning: optimal tuning parameters. Error: prediction error.

  **Method**        **\# clinical**   **\# gene**   **Tuning**                      **Error**
  ----------------- ----------------- ------------- ------------------------------- -----------
  Clinical-simple   7                 --            --                              0.371
  Clinical-TGDR     5                 --            *τ* = 0.8                       0.289
  Gene-TGDR         --                50            *τ* = 0.9                       0.267
  Cov-TGDR          3                 51            (*τ*~1~, *τ*~2~) = (1.0, 0.9)   0.227

###### 

Follicular Lymphoma Data: Cov-TGDR estimation. Variable: variable name (clinical) or Affymetrix Feature ID (genomic).

  **Variable**          **Estimate**   **Variable**   **Estimate**
  --------------------- -------------- -------------- --------------
  Clinical covariates                                 
  nodal                 0.123          pstat          0.194
  age                   0.450          stage          0.309
  ldh                   0.469          IPI.2          0.514
                                                      
  Genomic covariates                                  
  223710_at             −0.108         240593_x\_a    0.006
  225981_at             0.222          201739_at      −0.020
  226587_at             0.004          202783_at      −0.040
  230280_at             0.066          203612_at      0.040
  232204_at             −0.050         212713_at      −0.028
  232883_at             0.066          215536_at      −0.126
  234062_at             −0.036         208470_s\_a    0.214
  235058_at             −0.004         216950_s\_a    0.012
  239565_at             0.016          217893_s\_a    −0.110
  224280_s\_a           −0.202         219360_s\_a    0.056
  230938_x\_a           0.054          220235_s\_a    −0.090
  234792_x\_a           0.054                         

###### 

Analysis of Follicular lymphoma Data. \# clinical: number of clinical variables. \# gene: number of gene expressions. Tuning: optimal tuning parameters. Logrank: logrank statistics.

  **Method**        **\# clinical**   **\# gene**   **Tuning**                      **Logrank**
  ----------------- ----------------- ------------- ------------------------------- -------------
  Clinical-simple   7                 --            --                              17.9
  Clinical-TGDR     6                 --            *τ* = 0.1                       18.1
  Gene-TGDR         --                31            *τ* = 1.0                       4.0
  Cov-TGDR          6                 23            (*τ*~1~, *τ*~2~) = (0.1, 1.0)   23.9
